<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H72BC2CB9532D449EACDE495E07023353" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1393 IH: To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1393</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230307">March 7, 2023</action-date><action-desc><sponsor name-id="D000631">Ms. Dean of Pennsylvania</sponsor> (for herself and <cosponsor name-id="M000194">Ms. Mace</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.</official-title></form><legis-body id="H90575DDB7BD140C1A603D432FD154C12" style="OLC"><section section-type="section-one" id="HEBFC967D02BD4836B74E04DDACDB6F56"><enum>1.</enum><header>Currently accepted medical use with severe restrictions</header><subsection id="H89F745794654437EA092577644F9B740"><enum>(a)</enum><header>Definitions</header><text>Section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>) is amended—</text><paragraph id="H408F4F11C28040FFB1B5841C3EAADB20"><enum>(1)</enum><text>by redesignating paragraph (58) (defining a serious violent felony) as paragraph (59);</text></paragraph><paragraph id="H2997C4B091DD4A55B09CE8C0A77AFDF7"><enum>(2)</enum><text>by redesignating the second paragraph (57) (defining a serious drug felony) as paragraph (58); and</text></paragraph><paragraph id="H986E098F817D495B8FB9BB2D8A6B0199"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H21189E8AB9BC4D48980B5F009FAA18E0"><paragraph id="HE2958FD98AD746B5B269C93E38FE7FEE"><enum>(60)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H3FC619824AF940008E8CAEA4F6936647"><enum>(A)</enum><text>Subject to subparagraph (B), the term <term>currently accepted medical use with severe restrictions</term>, with respect to a drug or other substance, includes a drug or other substance that is an active metabolite, moiety, or ingredient (whether in natural or synthetic form) of an investigational new drug for which a waiver is in effect under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) or section 351(a)(3) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)(3)</external-xref>) and that the Secretary—</text><clause id="H283D4BC696E54EBB8E4DD3DE2D73BFE0" indent="up1"><enum>(i)</enum><text>designates as a breakthrough therapy under section 506(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(a)</external-xref>); or</text></clause><clause id="H9E13A26CD0ED4AC3B6F41FA8419FF85F" indent="up1"><enum>(ii)</enum><text>authorizes for expanded access under subsection (b) or (c) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>), either alone or as part of a therapeutic protocol, to treat patients with serious or life-threatening diseases for which no comparable or satisfactory therapies are available.</text></clause></subparagraph><subparagraph id="H30315DB6870F4A989C865BDE8B52A90C" indent="up1"><enum>(B)</enum><text>A drug or other substance shall not be treated as meeting the criteria under subparagraph (A) for having a currently accepted medical use with severe restrictions if—</text><clause id="HF0D43129A4C1403385FDEB36213DD74D"><enum>(i)</enum><text>in the case of a drug or other substance described in subparagraph (A)(ii)—</text><subclause id="H4C2CBDCE1994479FAFE1BDC396FC7699"><enum>(I)</enum><text>the Secretary places the expanded access or protocol for such drug on clinical hold as described in section 312.42 of title 21, Code of Federal Regulations (or any successor regulations);</text></subclause><subclause id="HC9D3ECF3A8C84ABD9A4F2AD0006DC8B5"><enum>(II)</enum><text>there is no other investigational new drug containing the drug or other substance for which expanded access has been authorized under section 561(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb(a)</external-xref>); and</text></subclause><subclause id="HE861C25EB6A14FF4A6B893EF9DE5CF88"><enum>(III)</enum><text>the drug or other substance does not meet the requirements of subparagraph (A)(i); or</text></subclause></clause><clause id="H84D98DE6C18F45F3A72C3852DFAD5A40"><enum>(ii)</enum><text>the drug or other substance is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H1460FCC292A844A8897BFC75A810E8B6"><enum>(b)</enum><header>Authority and criteria for classification of substances</header><text>Section 201(j) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811(j)</external-xref>) is amended—</text><paragraph id="H4E0F5528C6AC4886B4E2ACA2DBC20775"><enum>(1)</enum><text>in paragraph (1), by inserting <quote>a drug designated as a breakthrough therapy under section 506(a) of the Food Drug and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(a)</external-xref>), or a drug authorized for expanded access under subsection (b) or (c) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>),</quote> after <quote>subsection (f),</quote>;</text></paragraph><paragraph id="HD3ED3C68F2AD4AC4B7C4ED4AE20F62FD"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="H97CA5CC8AAE84158887FCCDC944D3DA1"><enum>(A)</enum><text>in subparagraph (A), by striking <quote>; or</quote> and inserting a semicolon;</text></subparagraph><subparagraph id="HF3BBEC5F61D54D38831401EEAB7ED7BE"><enum>(B)</enum><text>in subparagraph (B), by striking the period at the end and inserting a semicolon; and</text></subparagraph><subparagraph id="HC7797B9B67C044F6BA67EAC3963C846C"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H5A734808E8474DE9B577079005C13F83"><subparagraph id="H10E9808E3DE64721820D39CCB638F927"><enum>(C)</enum><text display-inline="yes-display-inline">the date on which the Attorney General receives notification from the Secretary of Health and Human Services that the Secretary has designated the drug as a breakthrough therapy under section 506(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(a)</external-xref>) or authorized the drug for expanded access under subsection (b) or (c) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>); or</text></subparagraph><subparagraph id="H0A7025A4AEB84EDE856F4D8614E975E2"><enum>(D)</enum><text display-inline="yes-display-inline">the date on which the Attorney General receives any written notification demonstrating that the Secretary, before the date of enactment of this subparagraph, designated the drug as a breakthrough therapy under section 506(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(a)</external-xref>) or authorized the drug for expanded access under subsection (b) or (c) of section 561 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>).</text></subparagraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HE62155EF0815492DAEC4270DC38378C3"><enum>(3)</enum><text>in paragraph (3), by inserting <quote>or paragraph (4)</quote> after <quote>paragraph (1)</quote>; and</text></paragraph><paragraph id="HCF90EDBE236A471C989CD885499A1AE9"><enum>(4)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H6C61EA8C3C3E4CFB8C3EE9281042A15B"><paragraph id="H3B1F343F1BB74A83B6F67C5AFA1F0633" indent="up1"><enum>(4)</enum><text>With respect to a drug moved from schedule I to schedule II pursuant to paragraph (1) and the expedited procedures described under this subsection, if the drug no longer has a currently accepted medical use with severe restrictions and the Secretary of Health and Human Services recommends that the Attorney General control the drug in schedule I pursuant to subsections (a) and (b), the Attorney General shall, not later than 90 days after receiving written notification from the Secretary, issue an interim final rule controlling the drug in accordance with such subsections and section 202(b) using the procedures described in paragraph (3) of this subsection.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section></legis-body></bill> 

